Indivior Pharmaceuticals, Inc. reports material agreement in SEC 8-K

Indivior Pharmaceuticals, Inc. filed an 8-K covering a material definitive agreement, an acquisition or disposition of assets, a direct financial obligation, and director or executive-officer changes. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.